cureapp.co.jp

What It Is

CureApp is a Japanese digital therapeutics company that aims to “re-create treatment” through software. Its core products are not general-purpose AI assistants, but prescription “therapeutic apps” designed for specific diseases. The website highlights CureApp HT, a treatment support app for hypertension; a treatment support app for reducing alcohol consumption; smoking cessation-related products; the ascure mobile health program for enterprises; and DTx-BASE for SaMD companies.

Core Capabilities

Based on the available text, CureApp’s technical focus is algorithmic intervention driven by medical evidence. Patients use their phones to record data such as blood pressure, behavior, and lifestyle status. The system analyzes each person’s condition based on medical knowledge, then provides personalized learning, goal setting, action recommendations, and encouragement. On the physician side, doctors can review blood pressure trends, behavioral changes, diary-style records, and generate patient reports and care plans. Its value lies in filling the “treatment gap” between outpatient visits and making lifestyle interventions more frequent and actionable.

Pricing and Business Model

The hypertension product is covered by insurance. There are no onboarding or maintenance fees for medical institutions, and billing is based on patient usage. The text lists Japan health insurance-related items: 90 points for guidance and management fees, 50 points as an initial introduction add-on, and 7,010 yen for specific insured medical materials, for up to 6 months. Standard pricing for other products and enterprise programs is not publicly disclosed and likely requires consultation.

Pros and Cons

Its strengths are clinical trials, pharmaceutical and medical device approval, insurance coverage, and guideline references, which together create a strong barrier to entry and make it suitable for serious medical settings. It also covers both the patient side and physician side, making behavior change more visible. The limitations are also clear: it does not disclose large language model or generative AI capabilities, algorithm transparency is limited, electronic medical record integration is still in preparation, and the products are highly dependent on Japan’s prescription, insurance, and regulatory systems. There is also no clear information on Chinese language support or cross-border use.

Who It’s For and Access from China

CureApp is better suited to Japanese medical institutions, chronic disease physicians, health insurance societies, and companies planning to develop software as a medical device, rather than ordinary users looking for a health app to download directly. Access from China and payment methods are not specified, so they should be considered unknown. If deployed in China, it would need to account for local medical device regulation, hospital system integration, health insurance payment, and data compliance. It can be compared with local chronic disease management, internet hospital follow-up, and digital therapeutics solutions.